A promising vaccine against pancreatic and colon cancer

Pancreas cancer remains one promising vaccine against pancreatic colon of the most dreaded cancers. Therefore, In France, around 5,000 new cases are diagnosed each year. For example, The five -year survival rate is less than 10 % according to the Inca (National Cancer Institute). Consequently. Consequently, Colorectal cancer, more frequent with nearly 45,000 new cases each year, is better supported but remains a major cause of mortality.

These cancers share a common point. However, The frequent presence of mutations in the KRAS gene, involved in the growth and survival of tumor cells. Similarly, These mutations make cancer cells resistant to conventional chemotherapy, which explains the difficulty in improving the prognosis.

Faced with this observation. Nevertheless. Nevertheless, research explores innovative strategies, and the ELI-002 2P experimental vaccine seems to represent a glimmer of hope for patients at risk of promising vaccine against pancreatic colon new relapse after surgery.

ELI-002 2P: How does this vaccine work? – Promising vaccine against pancreatic colon – Promising vaccine against pancreatic colon new

Unlike traditional vaccines. the ELI-002 2P is not promising vaccine against pancreatic colon intended to prevent the disease before its appearance. For example. It is designed to stimulate the immune system to attack the cancer cells already present, especially those that escape treatments.

It targets the G12D. G12R mutations of the Kras gene, present in approximately 90 % of pancreas cancers and 50 % of colorectal cancers. The vaccine uses amphiphile technology, which directs antigens directly to lymph nodes, where immune cells are formed and multiplied.

In practice. this means that the immune system learns to recognize. destroy specific tumor cells carrying these mutations, reducing the risk of recurrence. One of the great advantages of this vaccine is that it is “ready to use”. standardized, unlike personalized therapies with promising vaccine against pancreatic colon new Messenger RNA which require tailor -made production for each patient. This could allow wider, faster and less expensive access.

The results of the phase 1 clinical trial – Promising vaccine against pancreatic colon – Promising vaccine against pancreatic colon new

The promising vaccine against pancreatic colon AMPLIFY-2012 test. published in Nature Medicine. included 25 patients who have undergone surgery for pancreatic or colon cancer, presenting traces of circulating tumor DNA, indicative of a risk of relapse.

After an average follow -up of 20 months. the researchers observed:

• Immune response: 68 % of patients have developed a specific immune response to KRAS tumor cells.
• Survival without relapse: For patients with a strong immune response. median survival without recurrence has not been reached, while patients with lower response had a median survival of 3 months.
• Global survival: global median survival was 28.9 months, greater than historical data for these cancers.
• Complete disappearance promising vaccine against pancreatic colon new of tumor biomarkers: 24 % of patients have seen their tumor biomarkers disappear completely. which is a very positive indicator of efficiency.

These results are particularly encouraging because they show that the vaccine can induce sustainable immune responses. reduce the risk of relapse promising vaccine against pancreatic colon in high -risk patients.

Experimental vaccine: What follow -up for this revolution?

Why is this vaccine a potential revolution?

Several points make the ELI-002 2P a promising candidate:

1. Accessibility. speed: standardized production facilitates distribution and reduces costs compared to personalized vaccines.
2. Precise targeting: By attacking KRAS mutations, the vaccine acts directly on the tumor cells responsible for progression and resistance.
3. Durability of the answer: data show that the immune response can be maintained over time. a key factor to prevent relapses.

As Dr. William Tap. principal researcher of the test. points promising vaccine against pancreatic colon new out “This vaccine could transform the post-surgical management of pancreas and colon cancer, where the options remain very limited”.

The perspectives: phase 2. beyond

A phase 2 clinical trial is currently underway. aimed at confirming these results on a larger number of patients and comparing the effectiveness of promising vaccine against pancreatic colon the vaccine in relation to the absence of treatment. The first results were expected in 2026.

At the same time. an improved version, the ELI-002 7P, which targets a wider range of KRAS mutations, is in development. If these trials confirm the effectiveness observed in phase 1. the vaccine could become a major tool in prevention of recurrences of pancreas. colon cancer, bringing a real change in the prognosis of these diseases.

NAMELY

The CTDNA (circulating tumor DNA) makes it possible to detect very early on the. traces of blood in the promising vaccine against pancreatic colon new blood after surgery. even if the imagery is normal. In the ELI-002 2P trial. he helped identify patients at risk of relapse and target the vaccine where it would be the most effective.